Human pre-elafin inhibits a Pseudomonas aeruginosa-secreted peptidase and prevents its proliferation in complex media

被引:13
作者
Bellemare, Audrey [1 ,2 ]
Vernoux, Nathalie [1 ,2 ]
Morisset, Dany [1 ,2 ]
Bourbonnais, Yves [1 ,2 ]
机构
[1] Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1K 7P4, Canada
[2] Univ Laval, Ctr Rech Fonct, Quebec City, PQ G1K 7P4, Canada
关键词
D O I
10.1128/AAC.00585-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Pseudomonas aeruginosa is a life-threatening opportunist human pathogen frequently associated with lung inflammatory diseases, namely, cystic fibrosis. Like other species, this gram-negative bacteria is increasingly drug resistant. During the past decade, intensive research efforts have been focused on the identification of natural innate defense molecules with broad antimicrobial activities, collectively known as antimicrobial peptides. Human pre-elafin, best characterized as a potent inhibitor of neutrophil elastase with anti-inflammatory properties, was also shown to possess antimicrobial activity against both gram-positive and gram-negative bacteria, including P. aeruginosa. Its mode of action was, however, not known. Using full-length pre-elatin, each domain separately, and mutated variants of pre-elafin with attenuated antipeptidase activity toward neutrophil elastase, we report here that both pre-elafin domains contribute, through distinct mechanisms, to its antibacterial activity against Pseudomonas aeruginosa. Most importantly, we demonstrate that the whey acidic protein (WAP) domain specifically inhibits a secreted peptidase with the characteristics of arginyl peptidase (protease IV). This is the first demonstration that a human WAP-motif protein inhibits a secreted peptidase to prevent bacterial growth in vitro. Since several WAP-motif proteins from various species demonstrate antimicrobial function with variable activities toward bacterial species, we suggest that this mechanism may be more common than initially anticipated.
引用
收藏
页码:483 / 490
页数:8
相关论文
共 44 条
[1]   Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-κB [J].
Bingle, L ;
Tetley, TD ;
Bingle, CD .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2001, 25 (01) :84-91
[2]   Production of full-length human pre-elafin, an elastase specific inhibitor, from yeast requires the absence of a functional Yapsin 1 (Yps1p) endoprotease [J].
Bourbonnais, Y ;
Larouche, C ;
Tremblay, GM .
PROTEIN EXPRESSION AND PURIFICATION, 2000, 20 (03) :485-491
[3]   Pseudomonas aeruginosa protease IV enzyme assays and comparison to other pseudomonas proteases [J].
Caballero, AR ;
Moreau, JM ;
Engel, LS ;
Marquart, ME ;
Hill, JM ;
O'Callaghan, RJ .
ANALYTICAL BIOCHEMISTRY, 2001, 290 (02) :330-337
[4]   Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection [J].
Cantin, AM ;
Woods, DE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (04) :1130-1135
[5]   Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis [J].
Chernish, RN ;
Aaron, SD .
CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (06) :509-515
[6]   SELECTIVE-INHIBITION OF MICROBIAL SERINE PROTEASES BY ENAP-2, AN ANTIMICROBIAL PEPTIDE FROM EQUINE NEUTROPHILS [J].
COUTO, MA ;
HARWIG, SSL ;
LEHRER, RI .
INFECTION AND IMMUNITY, 1993, 61 (07) :2991-2994
[7]   ENAP-2, A NOVEL CYSTEINE-RICH BACTERICIDAL PEPTIDE FROM EQUINE LEUKOCYTES [J].
COUTO, MA ;
HARWIG, SSL ;
CULLOR, JS ;
HUGHES, JP ;
LEHRER, RI .
INFECTION AND IMMUNITY, 1992, 60 (12) :5042-5047
[8]   Characterization of human pre-elafin mutants:: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema [J].
Doucet, Alain ;
Bouchard, Dominique ;
Janelle, Marie France ;
Bellemare, Audrey ;
Gagne, Stphane ;
Tremblay, Guy M. ;
Bourbonnais, Yves .
BIOCHEMICAL JOURNAL, 2007, 405 (455-463) :455-463
[9]  
Engel LS, 1997, INVEST OPHTH VIS SCI, V38, P1535
[10]   The Pseudomonas aeruginosa genome -: How do we use it to develop strategies for the treatment of patients with cystic fibrosis and Pseudomonas infections? [J].
Erwin, AL ;
VanDevanter, DR .
CURRENT OPINION IN PULMONARY MEDICINE, 2002, 8 (06) :547-551